Background: Tumor-infiltrating lymphocytes (TILs) and expression of programmed cell death 1 (PD-1)/programmed death ligand-1 (PD-L1) are crucial for antitumor immunity. However, the status remains undetermined in HIV-infected colorectal cancer (CRC), limiting the use of immunotherapy in HIV-infected CRC patients.
Methods: We examined 27 HIV-infected patients and 120 non-HIV-infected patients with CRC from 2015-2020 at Shanghai Public Health Clinical Center. After matching the propensity score, 13 paired patients in the two groups were also compared. The expression of PD-1/PD-L1 as well as tumor-infiltrating CD4, CD8, and CD56 immune cells was examined using multiplex immunofluorescent analysis. The cell density for positive staining was calculated (cells/mm) and compared between HIV-infected and non-HIV-infected groups. In addition, the co-expression of PD-1 on immune cells and PD-L1 on tumor cells was compared in these two groups.
Results: The mean densities of tumor-infiltrating CD4, CD8, CD56 immune cells were 620.2, 261.2, and 0.2 cells/mm, respectively, in HIV-infected colorectal tumors compared with 698.6, 243, and 14 cells/mm in non-HIV-infected tumors. PD-1 expression was 227 cells/mm in HIV-infected tumors and 365.2 cells/mm in non-HIV-infected tumors. Besides, PD-L1 expression was 108.5 cells/mm in HIV-infected tumors and 126.8 cells/mm in non-HIV-infected tumors, and no significant difference was found between the two groups. Similarly, there were no significant differences in the expression of PD-1 on TILs and PD-L1 on tumor cells.
Conclusion: HIV-infected CRC patients had similar tumor-infiltrating lymphocytes (CD4 and CD8 T cells) compared to non-HIV-infected controls and substantially similar PD-1 expression on TILs and PD-L1 expression on tumors. These results support the inclusion of HIV-infected CRC patients in future immunotherapy trials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924460 | PMC |
| http://dx.doi.org/10.3389/fonc.2022.827596 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Efficacy of the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy for Advanced Classic Kaposi Sarcoma Treatment: A Single-Arm, Phase II Trial in the Elderly.
Cancer Res Commun
August 2024
National HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome, Italy.
Unlabelled: Kaposi sarcoma is a rare angioproliferative disease associated with human herpes virus-8 (HHV-8) infection. Kaposi sarcoma is frequent and aggressive in HIV-infected people, whereas the classic form (CKS) generally has an indolent course. Notably, all conventional therapies against Kaposi sarcoma have only temporary efficacy.
View Article and Find Full Text PDFHigher Neutrophil-to-Lymphocyte Ratio (NLR) Is a Preoperative Inflammation Biomarker of Poor Prognosis in HIV-Infected Patients with Colorectal Cancer: A Retrospective Study.
Can J Gastroenterol Hepatol
March 2023
Department of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Background: The serum systemic inflammation biomarkers are known predictors of colorectal cancer (CRC) patient prognosis. However, their significance in human immunodeficiency virus (HIV)-infected patients with CRC has not been studied. To address this gap, we conducted a retrospective study to evaluate the prognostic value of preoperative systemic inflammation biomarkers in HIV-infected patients with CRC.
View Article and Find Full Text PDFIncidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France.
PLoS One
April 2022
Aix-Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, France.
Background: We aimed to evaluate the incidence rates between 2010 and 2015 for invasive cervical cancer (ICC), breast cancer (BC), and colorectal cancer (CRC) in people living with HIV (PLWH) in France, and to compare them with those in the French general population. These cancers are targeted by the national cancer-screening program.
Setting: This is a retrospective study based on the longitudinal data of the French Dat'AIDS cohort.
Lymphocytes Infiltration and Expression of PD-1 and PD-L1 in Colorectal Cancer Between HIV-Infected and Non-HIV-Infected Patients: A Propensity Score Matched Cohort Study.
Front Oncol
March 2022
Department of General Surgery, The Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Background: Tumor-infiltrating lymphocytes (TILs) and expression of programmed cell death 1 (PD-1)/programmed death ligand-1 (PD-L1) are crucial for antitumor immunity. However, the status remains undetermined in HIV-infected colorectal cancer (CRC), limiting the use of immunotherapy in HIV-infected CRC patients.
Methods: We examined 27 HIV-infected patients and 120 non-HIV-infected patients with CRC from 2015-2020 at Shanghai Public Health Clinical Center.
Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals.
Front Immunol
March 2022
Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.
Article Synopsis
- This study evaluated the immune response to mRNA COVID-19 vaccines in people living with HIV (PLWH), focusing on antibody production and HIV viral load control.
- 131 PLWH were vaccinated and monitored for antibody levels and HIV-1 RNA at multiple time points post-vaccination, showing all had detectable antibodies without significant differences in viral load based on their HIV status.
- Results indicated minor fluctuations in HIV-1 RNA levels over six months, with no serious adverse effects, highlighting the safety and efficacy of mRNA vaccines for this population.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!